Retatrutide (also known as LY3437943) is an experimental synthetic peptide developed by Eli Lilly and Company that is currently undergoing Phase 3 clinical trials for obesity, Type 2 diabetes, and chronic weight management. It is known as a "triple-agonist" because it simultaneously targets three different metabolic hormone receptors in the body.
Looks like there are no reviews for this Product
Looks like there are no reviews for this product
China
We are a manufacturer and exporter of dermal fillers and a wide range of beauty and aesthetic products. As a dermal filler producer, we ensure high-quality standards, safety, and consistency across all our products for international markets.
China
